VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.25, sa.2, ss.50-54, 2019 (ESCI)
Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, patients should be tested for HBV serology and evaluated for antiviral therapy.